Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
GlobeNewswire
May 21, 2024
*Biodexa Pharmaceuticals PLC*
(“Biodexa” or the “Company”)
*Positive Statistically..